This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
keyboard_arrow_right

MAIN CONFERENCE DAY ONE

keyboard_arrow_leftSearch & Filter
search

MAIN CONFERENCE DAY ONE

search
7:15am - 8:15am60 mins
Registration and Coffee
    8:15am - 8:25am10 mins
    Keynote Presentations
    Welcome and Opening Remarks
    • Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
    • Paul Carter, PhD - Genentech Fellow, Department of Antibody Engineering, Genentech, Inc.
    8:25am - 9:10am45 mins
    Keynote Presentations
    Inspired by Nature: Translating Basic Science to Antibody Therapeutics
    • Janine Schuurman, Ph.D. - Corporate Vice President Research & Innovation, Genmab
    9:10am - 9:15am5 mins
    Keynote Presentations
    Keynote Questions
      9:15am - 10:00am45 mins
      Keynote Presentations
      The Adaptive Immune Receptor Repertoire (AIRR) in Human Disease and for Drug Discovery
      • George Georgiou, Ph.D. - Professor, Laura Jennings Turner Chair in Engineering, The University of Texas at Austin
      10:00am - 10:05am5 mins
      Keynote Presentations
      Keynote Questions
        10:05am - 10:35am30 mins
        Networking Refreshment Break
          10:35am - 11:20am45 mins
          Keynote Presentations
          Trispecific Antibodies for Treating Cancer and AIDS
          • Gary Nabel, M.D., Ph.D. - Chief Scientific Officer and Senior Vice President, Sanofi Global R&D
          11:20am - 11:25am5 mins
          Keynote Presentations
          Keynote Questions
            11:25am - 12:10pm45 mins
            Keynote Presentations
            Immunoglobulin A: Trojan Horse or Magic Bullet?
            • Marjolein van Egmond, Ph.D. - Professor of Oncology and Inflammation, Amsterdam University Medical Center
            12:10pm - 12:15pm5 mins
            Keynote Presentations
            Keynote Questions
              12:15pm - 1:15pm60 mins
              Scientific Luncheon Briefing 1
              Building Better Antibodies from Genes to Cell Lines
              • Claes Gustafsson, Ph.D. - Chief Commercial Officer and Co-Founder, ATUM
              12:15pm - 1:15pm60 mins
              Scientific Luncheon Briefing 3
              Implementing High-Throughput SPR in Recombinant Antibody Discovery and Library Development
              • Sara D'Angelo - VP of Library Development, Specifica, Inc.
              12:15pm - 1:15pm60 mins
              Scientific Luncheon Briefing 4
              Benchmarking Discovery-stage Antibodies from OmniChicken® against Clinical-stage Antibodies from Other Sources
              • Shelley Izquierdo, PhD - Director, Antibody Discovery, Ligand Pharmaceuticals
              12:15pm - 1:15pm60 mins
              Scientific Luncheon Briefing 5
              CAR-T, GPCRs, Antiviral bnAbs, Antivenom bnAbs: Precision Epitope Selection at Distributed Bio
              • Jacob Glanville - Co-Founder, CEO, President, Distributed Bio, Inc.
              12:15pm - 1:15pm60 mins
              Scientific Luncheon Briefing 2
              Quality. Speed. Value. Therapeutic Antibody Discovery in Challenging Projects Using AlivaMab® Mouse and AlivaMab Discovery Services
              • Larry Green, PhD - CEO, Ablexis & AlivaMab Discovery Services
              • John "Lippy!" Lippincott, PhD - Vice President of Research, AlivaMab Discovery Services
              1:15pm - 1:45pm30 mins
              Scientific Briefing 1
              An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design
              • Emilee Knowlton, Ph.D. - Immunology Sales Specialist, ProImmune Inc.
              1:15pm - 1:45pm30 mins
              Scientific Briefing 2
              Developability: Evaluating Specificity, Immunogenicity, Functionality, and Manufacturability for Lead Candidate Selection
              • Arron Hearn - Group Leader, Protein Engineering, Abzena
              1:15pm - 1:45pm30 mins
              Scientific Briefing 3
              Accelerated Full-scale Optimization of Antibodies Directed against Multipass Membrane Proteins
              • Ilse Roodink - Scientific Director, ImmunoPrecise Antibodies (Europe) B.V.
              1:15pm - 1:45pm30 mins
              Scientific Briefing 4
              Keys to Accelerated Protein Production & Biotherapeutic Development: Maximizing Transient CHO-based Productivity with Streamlined Migration to Stable Pools & Cell Line Generation.
              • Weili Wang - Director of Cell Culture & Protein Production, Maxcyte
              1:15pm - 1:45pm30 mins
              Scientific Briefing 5
              Optimization of E. coli SoluPro® using synthetic biology to a generate a high performance chassis microbe for scalable production of protein therapeutics
              • Johan Kers - Vice President of Research, AbSci
              1:45pm - 2:15pm30 mins
              Scientific Briefing 1
              Introduction of Alloy Therapeutics and the Alloy Gx Mice, A New in vivo Platform for the Discovery of Fully Human Antibodies
              • Heather Schwoebel - Vice President, Business Development & Operations, Alloy Therapeutics, LLC
              1:45pm - 2:15pm30 mins
              Scientific Briefing 2
              Exceptional Human Antibody Discovery with a Best-in-Class Transgenic Mouse
              • Linda Masat - Vice President of Business Development, Trianni, Inc.
              1:45pm - 2:15pm30 mins
              Scientific Briefing 3
              Comparison of in silico and Mammalian Display Technologies for Affinity Screening
              • Leona McGirr, Ph.D. - Team Leader-Affinity Maturation, Fusion Antibodies
              1:45pm - 2:15pm30 mins
              Scientific Briefing 4
              Making an Antibody-based Therapeutic in 60 days: High-throughput Discovery Applied to a Rapid Pandemic Response Platform
              • Kathryn Westendorf, MSc - Scientist, B Cell Biology, AbCellera
              1:45pm - 2:15pm30 mins
              Scientific Briefing 5
              Uncovering Critical Receptors and Assessing Target Specificity of Biotherapeutics
              • Jim Freeth, PhD - Co-Managing Director, Retrogenix, Ltd.
              2:25pm - 2:30pm5 mins
              Track 1: Antibody Libraries, Selection, Screening and Engineering
              Chairman’s Remarks
              • Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
              2:25pm - 2:30pm5 mins
              Track 2: Novel Therapeutic Targets and Non-Cancer Indications
              Co-Chairs’ Remarks
              • James Larrick, M.D., Ph.D. - Managing Director and Chief Medical Officer , Panorama Research, Inc.
              • David Shen, PhD - SVP, Biologics Research and CMC, NGM Biopharmaceuticals
              2:30pm - 3:00pm30 mins
              Track 2: Novel Therapeutic Targets and Non-Cancer Indications
              A Microbially Produced Antibody Format Formulated in Food for Modulating GI Tract Targets
              • Nico Callewaert - Professor, University of Ghent
              2:30pm - 3:00pm30 mins
              Track 1: Antibody Libraries, Selection, Screening and Engineering
              Drug-like Antibodies Straight from Selections: Enhanced Affinity and Developability from Specifica’s Generation 3 Platform
              • Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
              3:00pm - 3:30pm30 mins
              Track 1: Antibody Libraries, Selection, Screening and Engineering
              Immune Checkpoint Inhibitor Antibody Discovery, Optimization and Developability Enhancement by Mammalian Display
              • Michael Dyson - Chief Technology Officer, IONTAS Ltd.
              3:00pm - 3:30pm30 mins
              Track 2: Novel Therapeutic Targets and Non-Cancer Indications
              Development of anti-NKA Antibody for Heart Failure
              • Bo Yu - Co-founder and Chief Scientific Officer, Larix Bioscience LLC
              3:30pm - 4:00pm30 mins
              Track 1: Antibody Libraries, Selection, Screening and Engineering
              Targeting Antibody Discovery Using Directed Phospho Antibody-clonotype (DPAC)
              • Michael Weiner - VP, Molecular Sciences, AxioMx, an Abcam Company
              3:30pm - 4:00pm30 mins
              Track 2: Novel Therapeutic Targets and Non-Cancer Indications
              The Long Journey: From Mouse Linkage Studies to a Novel Therapeutic Target in Human Autoimmunity
              • William Ridgway, M.D. - Professor, University of Cincinnati
              4:00pm - 4:45pm45 mins
              Networking Refreshment Break and Opening of Exhibit and Poster Hall
                4:45pm - 5:15pm30 mins
                Track 1: Antibody Libraries, Selection, Screening and Engineering
                Antigen Discovery Driven by Efficient and Differential Phage Display Selection of Antibody Libraries on Cells
                • Christoph Rader - Professor, Department of Immunology and Microbiology, The Scripps Research Institute
                4:45pm - 5:15pm30 mins
                Track 2: Novel Therapeutic Targets and Non-Cancer Indications
                VasSF As a New Drug Development for Vasculitis including Blood Vessel Diseases - Recombinant Single-chain Fragment Variable Region of Human IgG
                • Kazuo Suzuki - CEO and President, A-CLIP Institute Co., Ltd
                5:15pm - 5:45pm30 mins
                Track 1: Antibody Libraries, Selection, Screening and Engineering
                Unbiased Specificity Assessment of Antibodies
                • Fridtjof Lund-Johansen - Senior Scientist, Oslo University Hospital, Rikshospitalet
                5:15pm - 5:45pm30 mins
                Track 2: Novel Therapeutic Targets and Non-Cancer Indications
                Antibody-mediated Targeting of Factor XII: Potential for Safe Anticoagulation and More
                • Con Panousis - Senior Director and Head of Molecular Biolog, CSL
                5:45pm - 6:15pm30 mins
                Track 1: Antibody Libraries, Selection, Screening and Engineering
                Triple Vector for Discovery of Antibody Molecules Fused to Fc
                • Maria Gonzalez-Pajuelo - Chief Scientific Officer, FairJourney Biologics
                5:45pm - 6:15pm30 mins
                Track 2: Novel Therapeutic Targets and Non-Cancer Indications
                Characterization of Critical Quality Attributes of mRNA, A Novel Modality for Therapeutic Antibody Engineering
                • Huijuan Li, PhD - Head, Analytical Development, Moderna Therapeutics
                6:15pm - 7:15pm60 mins
                Opening Night Networking Reception, Exhibits and Poster Viewing
                  Pre-Conference Training Course and Pre-Conference Workshops
                  NextMAIN CONFERENCE DAY TWO

                  Get the latest news.
                  As it happens

                  Sign up to get the latest on the agenda and speakers.
                  Filter
                  Streams
                  Formats
                  Choose Day